GE HealthCare Technologies Inc. (GEHC) Stock Analysis
A global imaging and diagnostics leader with a $21.8B backlog and AI-heavy moat—temporarily punished by tariffs and inflation—sets up a potentially sharp re-rating if margins recover.
Overview
GE Healthcare Technologies (GEHC), independent since its 2023 spin, is a global medtech leader delivering medical imaging, ultrasound, patient monitoring, pharmaceutical diagnostics, and digital solutions. With a 130+ year legacy, it serves ~1B patients annually through a vast ~5M-unit installed base, generating a resilient blend of capital equipment sales and recurring revenue from service contracts and consumable diagnostics drugs. Revenue is roughly ~66% product and ~34% services, with recurring revenue around ~50% today (target 60%) aided by contrast media, maintenance, and expanding SaaS. Strategically, GEHC is consolidating imaging and visualization into Advanced Imaging Solutions to accelerate cloud/AI adoption, leveraging 115 FDA AI authorizations and a strong $21.8B backlog. Its D3 ecosystem and high switching costs position it as a default partner for hospital refresh and digital transformation cycles, though near-term results are noisy from tariffs and inflation shocks.